Our results revealed that rosuvastatin can protect against cardiotoxicity associated with breast cancer therapy especially doxorubicin and trastuzumab documented by LVEF and proved by specific cardiac inflammatory marker, hs-cTnI and non-specific markers, MPO and IL-6. The gene discussed is TNNI3; the disease is breast cancer.